Pfizer Plans To Start Vaccinating Babies And Young Children Against
Health

Pfizer plans to start vaccinating babies and young children against Covid after the summer

The pharmacist will request authorization for children from two years of age in September, and for those older than six months in November.

Children with mask in class.

The American pharmaceutical company Pfizer declares that it plans to request approval before the end of this year. for emergency use of its Covid-19 vaccine among children of all ages.

Pfizer expects to apply for such authorization in the United States during the month of September in the case of children from 2 to 11 years old and in November for those from 6 months to 2 years old, as indicated in a presentation that accompanies the publication of its quarterly accounts.

The company – whose vaccine is currently authorized for people over 16 years of age – has already asked the US authorities to give the green light to emergency use in children between 12 and 15 years and, according to several sources, the go-ahead from Washington is expected to arrive next week.

In clinical trials, the vaccine developed by Pfizer and its German partner BioNTech showed 100% efficacy in that age group. The pharmaceutical company announced at the end of March the beginning of the tests of the product in children between 6 months and 11 years.

According to experts, immunization of children, which they account for about 20% of the US population, is essential to end the coronavirus pandemic, noting that the country is unlikely to achieve herd immunity until minors are also vaccinated.

In addition, Pfizer indicated that it plans to apply in July for emergency use authorization for a booster dose of its vaccine, a new injection that the pharmacist considers will be necessary to ensure immunization and to improve protection against variants of the virus.

Also, the company announced that it plans to request at the end of this month full approval of its vaccine in the US for those over 16 years of age, which until now is used thanks to an emergency authorization.

full approval would allow Pfizer to sell the vaccine directly to consumers and change its price, in addition to continuing to market the product once the health emergency in the country is lifted.

Some experts also point out that full authorization – which requires more data on safety and efficacy than the initial one – can help some citizens with doubts decide to get vaccinated.